Introduction
Most of the tumor suppressor genes in human cancers are originally identified by positional cloning of a chromosomal region that is defined by linkage analysis of the pedigrees in hereditary cancers (Figure 1 ) (White, 1992) . Subsequent studies often reveal that 2-hit inactivation of the relevant suppressor gene is also involved in a subset of the sporadic cancers from the same organ as the hereditary cancers or those from some other organs, indicating that alterations of these tumor suppressor genes act as rate-limiting factors in the development of both hereditary and sporadic cancers (Cavenee and White, 1995) . However, the numbers of hereditary cancers and their responsible genes are limited, while most of the adult human cancers, such as lung cancer, develop as sporadic diseases. In these tumors, additional genetic alterations, including inactivation of tumor suppressor genes associated with loss of heterozygosity (LOH) on the specific chromosomal regions, appeared to be responsible for multi-step carcinogenesis towards malignant tumors. Thus, identification of these genes would be crucial to a thorough understanding of the molecular mechanisms in carcinogenesis and tumor suppression.
One of the most common approaches to identifying a tumor suppressor gene in sporadic cancer is the positional cloning of the common region of LOH in the DNA from numbers of primary tumors, as described by Dr John Minna in this issue (Minna, 2002) . Chromosomal alterations in cancer cells, however, are extremely complicated, and it is often difficult to identify a single responsible gene from many candidate genes by LOH analysis alone, except for the cases associated with homozygous deletion (Figure 1 ) Li et al., 1997; Steck et al., 1997 ). An alternative approach towards a tumor suppressor gene is functional cloning, based on the genetic complementation of cancer cells with normal DNA fragments. In this article, the background, methodology, and significance of the functional cloning approach will be reviewed in sporadic cancers, and the identification of a novel tumor suppressor gene, TSLC1, in nonsmall cell lung cancer (NSCLC) by a series of methods will be described .
Two lines of study on tumor suppressor genes
The existence of a tumor-suppressor gene(s) was originally demonstrated by functional complementation through whole cell fusion. Harris et al. (1969) reported that the tumorigenic phenotype of three cancer cell lines was suppressed by fusion with mouse A9 fibroblasts. This is the first demonstration that the cancer phenotype acts in a recessive manner and that normal cells harbor a sort of gene that can suppress the malignant phenotype of cancer cells. Two years later, another important concept linking a tumor suppressor gene with a hereditary cancer was established independently by epidemiological and statistical studies on a childhood tumor, retinoblastoma. Knudson (1971) proposed that two independent genetic events were required to develop retinoblastoma, in which the first hit should be present in germline cells in hereditary cases. Thanks to the remarkable advance of the human genome project, research on hereditary cancer has made extraordinary progress in the last 15 years. Followed by the first demonstration of the human tumor suppressor gene, RB, in 1986 by positional cloning of 13q14, numbers of tumor suppressor genes were identified in hereditary cancers in the late 1980s to early 1990s (Friend et al., 1986; Haber et al., 1990; Xu et al., 1990; Groden et al., 1991; Nishisho et al., 1991; Kamb et al., 1994; Miki et al., 1994) . On the other hand, the functional cloning approach has developed relatively slowly but steadily, as will be described later.
Principles of functional complementation
Functional complementation of a tumor suppressor gene consists of two steps. The first is the introduction of a normal DNA or cDNA fragment into cancer cells lacking the function of the relevant gene. The second step is the assessment of a less malignant phenotype of the cells compared with that of the parental cancer cells. In the first step, the choice of the recipient cell is critical for the study on tumor suppressor genes, in which the cells that have substantially lost the function of the relevant genes should be used as recipients for genetic complementation. However, when functional cloning of an unknown tumor suppressor gene is to be started, information of the expression of the relevant gene is not available. Therefore, cancer cells showing LOH at the target chromosomal region are usually used as recipients on the speculation that the relevant gene in the remaining allele would also be inactivated. Even if the recipient cells express a significant amount of the relevant gene, transfer of an additional copy of the genes might confer some summation effects to the cells. Generally speaking, however, it would be tricky to assess the phenotypical changes caused by such a relative difference in the amount of the transcript or the gene product. The methodologies of gene transfer will be described in detail later.
In the second step, several assays are utilized as indicators of the malignant phenotype of cancer cells. These include assays in vivo, such as tumorigenicity or metastasis in the immunologically deficient mice, or those in vitro, such as colony formation in soft agar, rate of cell growth, or degree of cell death. Most of the cancer cell lines examined here are derived from the primary cancers in the advanced stage and carry multiple genetic alterations corresponding to their multi-stage carcinogenesis. Therefore, it would be a tough question whether the replacement of only one gene could sufficiently suppress some malignant phenotype of those cancer cells (Figure 2 ). Based on the empirical observations, however, it is reasonable to give an affirmative answer. Many tumor suppressor genes, including the p53, RB, and APC, are shown to suppress the malignant phenotype, at least in part, when introduced into cancer cells (Baker et al., 1990; Huang et al., 1988; Groden et al., 1995) .
We should also pay attention to the fact that the assays for the less malignant phenotype are essentially based on the negative selection of the cell growth. Therefore, it is impossible to design an assay to introduce a mixture of large numbers of different DNA or cDNA molecules from the relevant libraries into cancer cells and then pick up a very small subset of those cells that grow less efficiently. Some sophisticated studies were able to overcome the disadvantage of this negative selection and demonstrated the isolation of several genes, including the Krev1 and TSG101 (Noda et al., 1989; Li and Cohen, 1996) . This review, however, will focus on the studies that are associated with the transfer of a normal DNA fragment that is genetically defined as a candidate region harboring tumor suppressor genes in primary human tumors.
Another important issue to be considered in the functional cloning of a tumor suppressor is that the growth suppression by an exogenous gene is often observed not as a specific effect but as a non-specific cytotoxic or cytostatic effect when the gene is overexpressed by several artificial procedures. The level of gene expression is generally determined by two factors, a copy number of the transferred DNA and the activity of the gene promoter. From this point of view, a series of techniques of gene transfer is compared and summarized in Table 1 , paying special attention to the studies that used human cancer cells as recipients.
Method of gene transfer used for functional cloning

Whole cell fusion
Fusion of two different cells to construct a hybrid cell was initially reported in 1965 using HVJ (Sendai-virus) as fusogens (Murayama and Okada, 1965) . Using this method, Harris et al. (1969) fused the malignant cancer cell lines with mouse fibroblasts, A9, as described previously, and demonstrated that the tumorigenic phenotype of cancer cells was genetically recessive. After fusion, hybrid cells with polyploidy were often unstable in terms of chromosomal composition and reacquired tumorigenicity when they lost some specific chromosomes during the subsequent cell culture. These spontaneous 'revertant' cells provided more practical information about the chromosomes harboring possible tumor suppressor genes. Later, polyethylene glycol (PEG), instead of the Sendai virus, became widely used as a more effective fusogen to obtain hybrid cells (Pontecorvo, 1976) .
Microcell-mediated chromosome transfer
Treatment of cultured cells with a high dose of cytochalasin B, an inhibitor of actin polymerization, induces enucleation of the cells (Carter, 1967) . On the other hand, sustained exposure of cells to Colcemid, an inhibitor of microtubule polymerization, induces the formation of numerous microcells, each of which contains only one or a few chromosomes wrapped with a nuclear envelope as well as a plasma membrane (Prescott et al., 1972) . Combination of these highly sophisticated procedures made it possible to transfer a specific chromosome into the recipient cells as a microcell-mediated chromosome transfer (MMCT) (Fournier and Ruddle, 1977) . Hybrid cells containing transferred chromosomes can be selected either by endogenous markers, including the HPRT1 gene on chromosome X and the TK1 gene on chromosome 17, or exogenous indicators tagged with a transferred chromosome, such as the neomycin resistance gene. Functional evidence for the presence of many tumor suppressor genes on the specific chromosomes was provided by this approach in the late 1980s to the 1990s. In the course of transfer, chromosomes that are spontaneously fragmented are sometimes integrated into the recipient cells and give detailed knowledge of the possible gene locus. An important modification was then devised by irradiating chromosomes to smaller fragments of 2 to 20 centi-Morgans (cM) followed by MMCT (Dowdy et al., 1990; Koi et al., 1993) . This provides detailed information as to the loci for a tumor suppressor gene. In all these experiments, only a single copy of a chromosome is usually integrated into the recipient cells. Moreover, considering the large size of a chromosome, most of the genes on it appeared to be expressed under the control of its endogenous promoter. Thus, MMCT provides an ideal method to express a gene in a manner that closely resembles its endogenous expression. However, the summation effect of a large number of genes transferred through the chromosome could modify the phenotype as a noise of the assay and could mislead the interpretation of the results.
Transfer of YAC clones
Since the yeast artificial chromosome (YAC) can clone a long genomic DNA of up to several megabases (Mb) as an insert (Burke et al., 1987; Albertsen et al., 1990) , it could provide a new tool to transfer a normal DNA of the restricted region. Transfer of the YAC DNA into mammalian cells was initially demonstrated through spheroplast fusion using PEG in 1990 (Pavan et al., 1990a; Pachnis et al., 1990; Huxley et al., 1991) . Although successful transfers of the YAC are also demonstrated through microinjection (Schedl et al., 1993) or lipofection (Gnirke et al., 1991) , spheroplast fusion is the most efficient way to transfer a long DNA of more than 700 kb into cells intact, because it does not require gel purification of the YAC, which often induces breakage or rearrangement (Reeves et al., 1995) . One of the great advantages of YAC transfer is that only a single copy of the DNA is integrated into the chromosomal DNA of the host cells. In addition, several studies demonstrated that the genes in the central portion of the YAC are expressed through the endogenous promoter. Although the fact that the YAC has less stability than the chromosomal fragments, or other cloning systems requires careful evaluation of the results obtained, YAC transfer is an appropriate approach to narrow down the candidate region from a chromosomal fragment of more than several Mb to the segment of less than 1 Mb, which is appropriate to the subsequent screening of the candidate gene. The insert of the YAC derived from human genomic DNA contains multiple copies of the repetitive sequences, such as Alu. Therefore, when these sequences are targeted by the homologous recombination in yeast cells, a series of YAC derivatives truncated from either of its ends can be obtained from the parental YAC (Pavan et al., 1990b; Spencer et al., 1994) . This could further localize the relevant gene to the very restricted DNA fragment and confer an additional advantage to the YAC transfer as a tool for functional cloning.
Transfer of P1, BAC, and PAC clones
The bacteriophage P1 cloning system, the bacterial artificial chromosome (BAC), and the P1-derived artificial chromosome (PAC) are used to clone genomic DNA fragments of about 80 to 200 kb in size. The high stability and easy manipulation of these clones made them the most popular tools for the structural analysis of the genomic DNA, including sequencing. Furthermore, since the insert DNA can contain a full set of the gene sequence, including its promoter, when the gene is relatively small in size, these clones could also be utilized as tools for gene transfer. For this purpose, a subset of PAC libraries is designed to carry a mammalian selectable marker, such as the blasticidin-S-methylase gene, in the vector portions (Ioannou et al., 1994) . Thus, several pilot studies have been carried out to transfer P1, PAC, or BAC DNA into mammalian cells for the functional cloning of a tumor suppressor gene (Todd et al., 1996) . However, as long as the procedure of DNA transfer is based on lipofection, it is impossible to regulate the copy numbers of the integrated DNA, limiting the use of this approach for functional cloning. In fact, DNAs of one copy to more than 10 copies were integrated into the chromosome of the host cells in our preliminary experiment.
Expression of cDNA fragments by plasmid or viral vectors
The final step of functional cloning is carried out by the introduction of an expression vector carrying a cDNA fragment corresponding to the whole coding Functional cloning of a tumor suppressor in lung cancer Y Murakami sequence of the gene into the recipient cells. As mentioned above, the biological significance of this kind of experiment should be carefully evaluated after considering the level of gene expression caused by the increased copy numbers and a potent promoter. When stable cell clones are to be analysed, several independent cell clones are required that express the genes in the level equivalent to that in the corresponding normal tissues. Alternatively, if populations of the cells that transiently express the gene are to be analysed, highly efficient systems for the gene transfer, including those mediated by adenoviruses or retroviruses, should be considered.
Malignant phenotypes suppressed by genetic complementation
Among the approaches described above, MMCT has been the most widely used for studies on tumor suppressor genes. The representative results of monochromosomal transfer into human cancer cells are summarized in Table 2 . The patterns in the suppression of the malignant phenotype of cancer cells can be divided into five categories. The first group of genes induces apoptosis to the cells; the representative gene in this group is the p53. In fact, many studies have failed to obtain a hybrid cell when chromosome 17p, on which the p53 gene is located, is introduced into cancer cells lacking the p53 function (Goyette et al., 1992) . These observations are consistent with the fact that p53 is a strong inducer of cellular apoptosis. The second group of genes induces cellular senescence through the modification of the telomerase activity or some other mechanisms, although it is controversial whether these genes are to be categorized as tumor suppressor genes (Oshimura and Barrett, 1997) . The third group of genes inhibits cell growth in vitro after hybrid cells have been successfully isolated. When chromosome 13 harboring the RB1 gene was introduced into RB negative bladder cancer cells, the growth rate of the hybrid cells was significantly decreased in culture (Banerjee et al., 1992) . The p16/ INK4A gene on 9p12 also inhibits cell growth in vitro and can be grouped into this category (England et al., 1996) . Direct inhibition of the cell cycle progression by RB and p16 proteins corresponds well to these observations. The fourth group of genes induces neither apoptosis nor growth arrest when cultured in vitro. However, when the hybrid cells are injected into the back of nude mice, tumorigenicity of the parental cells is significantly suppressed. Some carefully designed experiments revealed that the tumors eventually appeared in mice after the long latency lost the transferred chromosomes, suggesting that the replacement of the chromosome is really correlated with the tumor suppression. The APC gene might fall into this category, at least in part, because replacement of chromosome 5 into a colon cancer cell line, SW480, lacking the APC function, strongly suppresses tumorigenicity in nude mice (Goyette et al., 1992) . The last group of genes does not affect tumor formation but inhibits metastasis in mice, indicating that the genes responsible for metastasis suppression are distinct from those responsible for tumor suppression in some cases (Yoshida et al., 2000) . The KAI-1 gene was isolated by functional complementation for metastasis in a rat prostate cancer cell line (Dong et al., 1995) .
As summarized in Table 2 , the patterns of suppression of the malignant phenotype vary depending on not only the chromosomes or genes to be transferred but also the types of the recipient cells and the tissues they are derived from. Among the five categories, however, the fourth one, namely, direct suppression of tumorigenicity in nude mice, is most often reported when chromosomes carrying unknown tumor suppressors are introduced into cancer cells. Identification and characterization of this group of genes would be important because they could provide novel molecular targets for the treatment of advanced human cancers. However, since a single gene responsible for tumor suppression has not been cloned by this approach, an alternative possibility could not be excluded, namely, that the tumor suppression observed in vivo might be due to the summation effect of large numbers of genes introduced by chromosome transfer. As a lung tumor suppressor gene, TSLC1, has recently been identified as a novel suppressor in the fourth category by a series of functional complementation, the process of identification will be summarized, and the significance of this approach will be discussed for the study on tumor suppression in sporadic cancers .
Genetic alterations in human NSCLC
NSCLC, like most other human neoplasms, develops and progresses towards malignant tumors through multiple steps caused by the multiple genetic alterations (Weinberg, 1996; Sekido et al., 1998) . Numerous genetic alterations, including mutations of the K-ras and N-ras genes (Rodenhuis et al., 1988; Suzuki et al., 1990) and inactivation of the tumor suppressor p53 (Takahashi et al., 1989; Kishimoto et al., 1992) , RB (Sachse et al., 1994) , and p16/INK4A genes have been reported in NSCLC. Furthermore, LOH on specific chromosomal regions, including 3p, 13q, 17p, and 11q, has also been observed at high frequency in advanced NSCLC tumors or their metastatic lesions in brain, suggesting the involvement of additional tumor suppressor genes (Weston et al., 1989; Kawanishi et al., 1997; Kohno and Yokota, 1999) . Some of these genes, including the p73 and the p51 genes, have already been identified and found to be involved in a small subset of NSCLC (Table 3 ) (Nomoto et al., 1998; Sunahara et al., 1999) . When focused on chromosome 11q, several independent studies on detailed LOH indicate that multiple tumor suppressor genes are present in this region, including the PPP2R1B gene at 11q23-24 (Rasio et al., 1995; Wang et al., 1998) . However, identification of a tumor Satoh et al. (1993) through MMCT, using a human adenocarcinoma cell line, A549, as a recipient. A549 is an appropriate recipient cell because it is highly tumorigenic in the back of nude mice and one allele of its chromosome 11q is completely lost. An independent study on LOH in 79 primary NSCLC tumors revealed that a fragment of 11q23 of about 5 cM was commonly deleted (Iizuka et al., 1995) . Since this region was covered with five continuous YAC clones (Arai et al., 1996) , we transferred these YACs into A549 cells one by one through spheroplast fusion instead of transferring a whole chromosome 11. Analysis of the tumorigenicity of these hybrid cells revealed that the suppressor activity was present within a YAC clone, 939b12, of 1.6 Mb ( Figure 3 ) . Next, we fragmented the YAC clone, 939b12, and obtained a series of truncated derivatives that retained the centric end but deleted various fragments at the acentric side of the YAC. Subsequent studies for tumorigenicity revealed that a predicted tumor suppressor gene, which we named TSLC1 (tumor suppressor in lung cancer-1), lay within a central 700-kb fragment in YAC 939b12 on chromosome 11q23.2. Most of the suppressor activity further localized to a 100-kb segment, because tumorigenicity is strongly suppressed in cells transferred with truncated clones containing 1100 kb of the parental YAC but not in those transferred with a 1000 kb truncated derivative .
Structural analysis of the candidate region, including construction of BAC and PAC contigs, revealed that one PAC clone contained an insert covering a whole candidate region of 100 kb. Since this PAC was derived from an RPCI-6 library and contained the blasticidin resistance gene in its vector, the PAC DNA was isolated and directly introduced into A549 cells by lipofection. However, none of the transfectant cells showed tumor suppressor activity, suggesting that the candidate region of 100 kb might not contain a whole unit of the TSLC1 gene. On the other hand, concurrent structural analysis of this region identified a single candidate gene, TSLC1 (Figure 3) . A full-length cDNA was constructed and found to be identical to that of the human genes, BL2 and IGSF4 (Gomyo et al., 1999) . The TSLC1 spans more than 300 kb on 11q23.2, while neither exon 1 nor the promoter sequence is located within the 100-kb fragment. This could correspond to the lack of suppressor activity by the PAC clone of 100 kb.
TSLC1 consists of 10 exons and is predicted to encode a membrane glycoprotein of 442 amino acids that shows significant homology with the neural cell adhesion molecule (NCAM) and several other immunoglobulin superfamily proteins, suggesting possible involvement in the interaction of cells with other cells and/or the extracellular matrix (Figure 4a ). The tumor suppressor activity of the TSLC1 was finally determined by comparing A549 cells transfected with the plasmids containing a full-length cDNA with those containing a truncated cDNA or a vector alone. Three independent cell clones carrying the full-length TSLC1 cDNA showed strong tumor suppressor activity. Two of these clones expressed TSLC1 at the level equivalent to that in normal lung, suggesting that a non-specific cytotoxic or cytostatic effect might be neglected, at least in these two cell clones. In contrast, cell lines expressing a trunctated TSLC1 or carrying a vector alone showed a fully tumorigenic phenotype. We concluded from these results that the TSLC1 is responsible for tumor suppression in our experimental system in nude mice.
Two-hit inactivation of the TSLC1 in primary human NSCLC tumors
Next, we examined the two-hit inactivation of the TSLC1 in primary NSCLC and other tumors in order to determine whether the TSLC1 is really involved in human tumors (Table 4) . LOH at the TSLC1 locus on 11q23.2 was detected in 42, 33 and 17% of the primary NSCLC, hepatocellular carcinoma (HCC), and pancreatic cancer (PaC), respectively. Northern blot analysis showed that the expression of the TSLC1 was completely lost or markedly reduced in six out of 12 NSCLC cell lines, including A549. SSCP and sequencing analyses demonstrated that, in association with LOH, inactivating mutations, including a frameshift and a missense mutation, were involved in a small subset of primary NSCLC and HCC tumors. Further- Functional cloning of a tumor suppressor in lung cancer Y Murakami more, bisulfite sequencing analysis revealed that the CpG sites in the promoter region of the TSLC1 were hypermethylated in about 40% of primary NSCLC and 25 -30% of HCC and PaC tumors. The incidence of hypermethylation was especially high in tumors showing LOH at the TSLC1 locus. Since the methylation status of the promoter sequence strongly correlates with the gene expression in many cancer cell lines, these observations strongly suggest that the silencing of the TSLC1 by the promoter methylation is involved in the majority of primary tumors of NSCLC, HCC, and PaC showing LOH on 11q23.2. Based on these results, we concluded that the TSLC1 is a novel tumor suppressor gene in human NSCLC ).
Definition of a tumor suppressor gene in sporadic cancer
The molecular mechanisms of gene inactivation of the TSLC1 are summarized in Figure 5 . As many studies have pointed out, promoter methylation is an (right) were injected into the back of Balb/c nu/nu mice. Tumor incidence was determined 10 weeks after injection, as described previously Kuramochi et al., 2001 important mechanism to inactivate a suppressor gene in sporadic cancers (Merlo et al., 1995; Rountree et al., 2001) . Therefore, failure in detecting inactivating mutations in a limited number of samples does not necessarily exclude the possibility that the gene is a biologically important tumor suppressor. However, the presence of promoter methylation in tumors alone is not a sufficient criterion to define the gene as a tumor suppressor because several genes, whose functions are not necessary for the growth of cancer cells, are also silenced by methylation (Ahuja et al., 1998) . Therefore, the presence of tumors with inactivating mutations, even with low incidence, provides potent supportive evidence for the tumor suppressor gene. We must note, however, that cancer cells are monoclonal in origin and carry various random mutations in addition to causative mutations through their genetic instability (Murakami et al., 1995; Thiagalingam et al., 1996; Lengauer et al., 1997) . Thus, we propose that the final determination of a tumor suppressor gene requires functional evidence for the suppression of the malignant phenotype of cancer cells, paying special attention to exclude the non-specific cytotoxic or cytostatic effect by artificial gene expression. All suppressor genes recently identified in sporadic cancers, including the RASSF1 (Dammann et al., 2000) , ST7 (Zenklusen et al., 2001) , and KLF6 (Narla et al., 2001) , as well as TSLC1 , meet these criteria.
Significance of functional complementation in the study of human cancers
The importance of functional complementation in identifying a tumor suppressor gene was described using the TSLC1 as one of the examples. Further, the functional cloning approach provides basic knowledge as well as questions for the understanding of the mechanisms of tumor suppression. The first lesson we have learned here is that this approach can identify a gene that significantly suppresses the tumor formation of cancer cells with multiple genetic alterations. While A549 cells are derived from an advanced lung adenocarcinoma and carry gene aberrations of the Kras and p16/INK4A , the restoration of the TSLC1 expression to a normal level is sufficient to substantially suppress the tumorigenicity of A549. The responsible TSLC1 gene encodes a membrane glycoprotein and belongs to immunoglubulin superfamily proteins that are probably involved in cell-to-cell or cell-to-substrate interactions. This clearly indicates that TSLC1 does not function directly at the downstream of the known pathways of K-ras or p16 but is involved in some distinct cascades that are specific to the cell growth in vivo.
The second point that should be noted is that the expression of TSLC1 does not significantly affect the cell growth in vitro, categorizing this gene into the fourth group of genes in Table 2 . In other words, functional cloning through tumor suppression in nude mice has an advantage, namely, that it brings up a new group of molecules that have the potential to inhibit tumor growth without conferring any direct cytotoxicity to the cells in vitro. Considering TSLC1 as a possible therapeutic target, the absence of direct cytotoxicity to the cells might be rather beneficial to protect patients from the harmful side effects that are seen in the course of chemotherapy against cancer.
The final and ultimate question is, then, what tumorigenicity means. Tumorigenicity in nude mice has been recognized as the most reliable indicator of malignant features in cancer cells (Fogh et al., 1977) . In fact, it would represent a relatively common cascade of human tumorigenesis rather than that specific to NSCLC. Ubiquitous expression of the TSLC1 and its alteration in a wide range of tumors, including NSCLC, HCC, and PaC, would support this hypothesis. However, the molecules or cascades that are directly involved in the tumorigenicity of cancer cells have not been characterized in detail. It is promising that the TSLC1 expression correlates well with tumorigenicity, not only in A549 but also in several other NSCLC cell lines. As summarized in Table 5 , all five additional cell lines lacking TSLC1 expression are strongly tumorigenic, whereas at least two cell lines that substantially express TSLC1 show reduced tumorigenicity or none at all (Fogh et al., 1977; Santon et al., 1986; Ohsaki et al., 1996; Yamori et al., 1997; Aoe et al., 1999) . Furthermore, two of the cell lines lacking TSLC1 are originally derived from pleural fluid and can grow in liquid culture. Taken together, these observations indicate that cell-to-cell or cell-tosubstrate interaction would be one of the critical components that participate in the suppression of tumorigenicity in nude mice. It is noteworthy that the gene products of the TSLL1 and TSLL2, which are isolated as homologous genes to TSLC1, also appear to be involved in cell adhesion and lose their expression in various human cancer cells (Figure 4b) . In patients, disruption of cell adhesion might correspond to the invasion or metastasis of cancer cells to adjacent or distal tissues. E-cadherin, an important cell adhesion molecule, also acts as a critical tumor suppressor gene in gastric and several other human cancers including NSCLC (Oda et al., 1994; Birchmeier, 1995) . However, if the TSLC1 of a cell adhesion molecule acts as simple glue, the presence of TSLC1, rather than its absence, might possibly assist tumor formation in nude mice. This dilemma could be dissolved if TSLC1 were involved in the negative signals for cell growth that were turned on by cell adhesion or if TSLC1 could induce cell death when cell adhesion is hampered. Several pioneer studies have demonstrated that some adhesion molecules, including DCC and CEA, are involved in anoikis, one of the apoptotic mechanisms of epithelial cells induced by detachment from adjacent cells or substrates (Mehlen et al., 1998; Ordonez et al., 2000; Frisch and Screaton, 2001) . Further studies would be required to elucidate the role of TSLC1 and its cascade in the suppression of tumorigenesis. of the TSLC1 gene and Drs Takeshi Fukami, Mari Masuda, Mika Yageta, and Kana Isogai for their involvement in the initial characterization of the TSLC1 protein. Dr Takao Sekiya is gratefully acknowledged for his participation in helpful discussions and his invaluable support of the project. The author sincerely acknowledges 
